within Pharmacolibrary.Drugs.ATC.L;

model L01EX11_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 6.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.11,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Quizartinib is an oral, selective type II FLT3 inhibitor used in the treatment of acute myeloid leukemia (AML) with FLT3-ITD mutations. It is approved for use in adult patients and has demonstrated efficacy in relapsed or refractory AML.</p><h4>Pharmacokinetics</h4><p>Single-dose administration to healthy volunteers; parameters from noncompartmental analysis.</p><h4>References</h4><ol><li><p>Li, J, et al., &amp; Gammon, G (2020). Effect of Food on the Pharmacokinetics of Quizartinib. <i>Clinical pharmacology in drug development</i> 9(2) 277–286. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.770&quot;>10.1002/cpdd.770</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31916418/&quot;>https://pubmed.ncbi.nlm.nih.gov/31916418</a></p></li><li><p>Qi, J, et al., &amp; Wang, J (2024). Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China. <i>Clinical pharmacology in drug development</i> 13(5) 560–571. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1353&quot;>10.1002/cpdd.1353</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38284515/&quot;>https://pubmed.ncbi.nlm.nih.gov/38284515</a></p></li><li><p>Li, J, et al., &amp; Gammon, G (2019). Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. <i>British journal of clinical pharmacology</i> 85(9) 2108–2117. DOI:<a href=&quot;https://doi.org/10.1111/bcp.14022&quot;>10.1111/bcp.14022</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31173645/&quot;>https://pubmed.ncbi.nlm.nih.gov/31173645</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EX11_1;
